Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of antibiotic-resistant lactic acid bacteria on adverse events of H. pylori eradication therapy
jRCTs051180155Completed
- Sponsor
- Biofermin Pharmaceutical
- Start
- Jun 2018
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Randomised trial in Helicobacter pylori infection and antibiotic-associated diarrhea (AAD) comparing Biofermin R arm with Placebo arm (2 arms). Primary endpoint: Incidence of diarrhea during H. pylori eradication therapy (day 0 to day 6). Started Jun 2018; status: completed.
02
Drugs
Biofermin R
03
Conditions
Helicobacter pylori infectionantibiotic-associated diarrhea (AAD)
Beyond the preview
Go deeper on jRCTs051180155.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051180155.